Loading resource…

UpToDate, Inc.
The document outlines critical information regarding sacubitril and valsartan, a combination medication used primarily for heart failure management. It details the pharmacologic properties, dosing recommendations for adults, and important safety alerts, including potential risks during pregnancy. Additionally, it discusses the implications of switching from other heart failure medications and provides insights into drug interactions and monitoring requirements.
Sign in to open
Answers use this document only.
Your first question is free.
Resources from the same specialty and type. Curated links will replace these when added.
Documents that extend or complement this resource.

Cost Effective Heart Failure Care - St. Mary's Lacor
Same clinical topic · Cardiology

Cardio Oncology Practice Manual A Companion to Braunwalds Heart
Same clinical topic · Cardiology

The Heart-Brain Connection
Same clinical topic · Cardiology

Cardiology in the ER: A Practical Guide
Same clinical topic · Cardiology

NITROGLYCERIN (GLYCERYL TRINITRATE): DRUG INFORMATION
Same clinical topic · Cardiology

CLOPIDOGREL: DRUG INFORMATION
Same clinical topic · Cardiology

CRITERIA FOR THE DIAGNOSIS OF CARDIOGENIC SHOCK—EUROPEAN PERSPECTIVE: A CLINICAL CONSENSUS STATEMENT
Same specialty · Cardiology

2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Same specialty · Cardiology

2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure
Same specialty · Cardiology